المؤلفون: Gouez M; Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.; Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.; Inserm, U1296 Unit, 'Radiation: Defense, Health and Environment', Centre Léon Bérard, Lyon, France., Rébillard A; Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France.; Institut Universitaire de France, Paris, France., Thomas A; Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France., Beaumel S; CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France., Matera EL; CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France., Gouraud E; Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France., Orfila L; Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France., Martin B; Movement, Sport, and Health Sciences Laboratory, EA 1274, Université Rennes 2, ENS Rennes, Bruz, France., Pérol O; Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.; Inserm, U1296 Unit, 'Radiation: Defense, Health and Environment', Centre Léon Bérard, Lyon, France., Chaveroux C; CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France., Chirico EN; Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, United States., Dumontet C; CRCL INSERM 1052/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France., Fervers B; Prevention Cancer Environment Department, Léon Bérard Cancer Center, Lyon, France.; Inserm, U1296 Unit, 'Radiation: Defense, Health and Environment', Centre Léon Bérard, Lyon, France., Pialoux V; Team Atherosclerosis, Thrombosis and Physical Activity, LIBM EA7424, Université Claude Bernard Lyon 1, Université de Lyon, Faculty of Medicine, Lyon, France.

المصدر: Frontiers in immunology [Front Immunol] 2024 Feb 15; Vol. 15, pp. 1368550. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024).

نوع المنشور: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms*/therapy , Physical Conditioning, Animal*, Animals ; Mice ; Apoptosis ; Disease Models, Animal ; Immunotherapy/methods ; Tumor Microenvironment

المؤلفون: Macauda A; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany., Briem K; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany., Clay-Gilmour A; Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA., Cozen W; Division of Hematology/Oncology, Division of Hematology/Oncology, Department of Medicine, School of Medicine, Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California at Irvine, Irvine, CA, USA., Försti A; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany., Giaccherini M; Department of Biology, University of Pisa, Pisa, Italy., Corradi C; Department of Biology, University of Pisa, Pisa, Italy., Sainz J; Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS, Granada, Spain.; Instituto de Investigación Biosanitaria IBs.Granada, Granada, Spain.; Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain., Niazi Y; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany., Ter Horst R; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Li Y; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.; Centre for Individualised Infection Medicine (CiiM) & TWINCORE, joint ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany., Netea MG; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.; Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany., Vogel U; National Research Centre for the Working Environment, Copenhagen, Denmark., Hemminki K; Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, Czech Republic.; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Slager SL; Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Varkonyi J; Department of Hematology, Semmelweis University, Budapest, Hungary., Andersen V; Molecular Diagnostics and Clinical Research Unit, Institute of Regional Health Research, University Hospital of Southern Denmark, Odense, Denmark.; Institute of Regional Research, University of Southern Denmark, Odense, Denmark.; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Iskierka-Jazdzewska E; Department of Hematology, Transplantology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland., Mártinez-Lopez J; Hospital Universitario 12 de Octubre, Instituto de Investigación del Hospital Universitario 12 de Octubre, 28041, Madrid, Spain., Zaucha J; Department of Haematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland., Camp NJ; Division of Hematology and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Druzd-Sitek A; Department of Lymphoproliferative Diseases, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Bhatti P; Cancer Control Research, BC Cancer, Vancouver, BC, Canada.; Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Chanock SJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kumar SK; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Subocz E; Department of Hematology, Warmian-Masurian Cancer Center of The Ministry Of The Interior And Administration's Hospital, Olsztyn, Poland., Mazur G; Wroclaw Medical University, Wroclaw, Poland., Landi S; Department of Biology, University of Pisa, Pisa, Italy., Machiela MJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jerez A; Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, Murcia, Spain., Norman AD; Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Hildebrandt MAT; Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadar K; St. John's Hospital, Budapest, Hungary., Berndt SI; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ziv E; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Buda G; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Nagler A; Hematology Division Chaim Sheba Medical Center, Tel Hashomer, Israel., Dumontet C; INSERM 1052/CNRS 5286, CRCL, Lyon, France., Raźny M; Department of Hematology, Rydygier Specialistic Hospital, Cracow, Poland., Watek M; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.; Department of Hematology, Holycross Cancer Center, Kielce, Poland., Butrym A; Wroclaw Medical University, Wroclaw, Poland.; Alfred Sokolowski Specialist Hospital in Walbrzych Oncology Support Centre for Clinical Trials, Wałbrzych, Poland., Grzasko N; Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland., Dudzinski M; Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland., Rybicka-Ramos M; Department of Hematology, Specialist Hospital No.1 in Bytom, Academy of Silesia, Faculty of Medicine, Katowice, Poland., Matera EL; INSERM 1052/CNRS 5286, CRCL, Lyon, France., García-Sanz R; University Hospital of Salamanca, Diagnostic Laboratory Unit in Hematology, University Hospital of Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Goldschmidt H; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany., Jamroziak K; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Jurczyszyn A; Hematology Department, Jagiellonian University Medical College, Cracow, Poland., Clavero E; Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain., Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia., Pelosini M; U.O. Dipartimento di Ematologia, Azienda USL Toscana Nord Ovest, Livorno, Italy., Zawirska D; Department of Hematology, University Hospital, Crakow, Poland., Kruszewski M; Department of Hematology, University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland., Marques H; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal., Haastrup E; Department of Clinical Immunology, the Bloodbank, Rigshospitalet, Copenhagen University Hospital, København, Denmark., Sánchez-Maldonado JM; Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS, Granada, Spain.; Instituto de Investigación Biosanitaria IBs.Granada, Granada, Spain., Bertsch U; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Rymko M; Department of Hematology, Provincial Polyclinical Hospital in Torun, Torun, Poland., Raab MS; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Brown EE; Department of Pathology, School of Medicine at the University of Alabama, Birmingham, AL, USA., Hofmann JN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vachon C; Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Campa D; Department of Biology, University of Pisa, Pisa, Italy., Canzian F; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. f.canzian@dkfz.de.

المصدر: Leukemia [Leukemia] 2023 Nov; Vol. 37 (11), pp. 2326-2329. Date of Electronic Publication: 2023 Sep 18.

نوع المنشور: Letter; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/genetics, Humans ; Genetic Loci ; Genetic Predisposition to Disease ; Polymorphism, Single Nucleotide ; Genome-Wide Association Study

المؤلفون: Chettab K; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France.; Hospices Civils de Lyon, Lyon, France., Fitzsimmons C; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Novikov A; HEPHAISTOS-Pharma, Université Paris-Saclay, Orsay, France., Denis M; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France.; Antinéo, Lyon, France., Phelip C; HEPHAISTOS-Pharma, Université Paris-Saclay, Orsay, France., Mathé D; Antinéo, Lyon, France., Choffour PA; Antinéo, Lyon, France., Beaumel S; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Fourmaux E; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Norca P; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Kryza D; Hospices Civils de Lyon, Lyon, France., Evesque A; Antinéo, Lyon, France., Jordheim LP; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Perrial E; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Matera EL; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France., Caroff M; HEPHAISTOS-Pharma, Université Paris-Saclay, Orsay, France., Kerzerho J; HEPHAISTOS-Pharma, Université Paris-Saclay, Orsay, France., Dumontet C; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon, France.; Hospices Civils de Lyon, Lyon, France.

المصدر: Frontiers in immunology [Front Immunol] 2023 May 08; Vol. 14, pp. 1066402. Date of Electronic Publication: 2023 May 08 (Print Publication: 2023).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Adjuvants, Immunologic* , Lipopolysaccharides* , Toll-Like Receptor 4*/agonists, Animals ; Dogs ; Humans ; Mice ; Cytokines ; Liposomes

المؤلفون: Denis M; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; R&D Department, Antineo, Lyon, France., Mathé D; R&D Department, Antineo, Lyon, France., Micoud M; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Choffour PA; R&D Department, Antineo, Lyon, France., Grasselly C; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Matera EL; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Dumontet C; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Hematology Department, Hospices Civils de Lyon, Lyon, France.

المصدر: Frontiers in immunology [Front Immunol] 2023 Jan 10; Vol. 13, pp. 1011943. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/therapy , Immune Checkpoint Inhibitors*/pharmacology , Drug Resistance, Neoplasm*, Animals ; Mice ; Disease Models, Animal ; Immunotherapy/methods

المؤلفون: Denis M; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Antineo, Lyon, France., Grasselly C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Antineo, Lyon, France., Choffour PA; Antineo, Lyon, France., Wierinckx A; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Mathé D; Antineo, Lyon, France., Chettab K; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Tourette A; Antineo, Lyon, France., Talhi N; Antineo, Lyon, France., Bourguignon A; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Birzele F; Roche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Kress E; Antineo, Lyon, France., Jordheim LP; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Matera EL; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Dumontet C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Hospices Civils de Lyon, Lyon, France.

المصدر: Cancer immunology research [Cancer Immunol Res] 2022 Aug 03; Vol. 10 (8), pp. 1013-1027.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: B7-H1 Antigen*/genetics , Fatty Acids, Nonesterified*, Animals ; Cell Line, Tumor ; Humans ; Mice ; Neoplasm Recurrence, Local ; Tumor Microenvironment

المؤلفون: Chettab K; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France.; Hospices Civils de Lyon, Centre Hospitaller Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite 69310, France., Matera EL; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France., Lafond M; LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Université Lyon, Lyon F-69003, France., Coralie D; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France., Favin-Lévêque C; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France., Goy C; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France., Strakhova R; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France., Mestas JL; LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Université Lyon, Lyon F-69003, France., Lafon C; LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Université Lyon, Lyon F-69003, France., Dumontet C; INSERM U1052, CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Lyon 69008, France.; Hospices Civils de Lyon, Centre Hospitaller Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-Bénite 69310, France.

المصدر: Molecular pharmaceutics [Mol Pharm] 2022 Mar 07; Vol. 19 (3), pp. 929-935. Date of Electronic Publication: 2022 Feb 11.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Erythrocytes* , Microbubbles*, Humans

المؤلفون: Conilh L; Mablink Bioscience, 69 rue de la république, 69002 Lyon, France.; Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université de Lyon, 69008 Lyon, France., Fournet G; Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, UMR CNRS 5246, Université de Lyon, 69100 Villeurbanne, France., Fourmaux E; Mablink Bioscience, 69 rue de la république, 69002 Lyon, France.; Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université de Lyon, 69008 Lyon, France., Murcia A; Mablink Bioscience, 69 rue de la république, 69002 Lyon, France.; Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, UMR CNRS 5246, Université de Lyon, 69100 Villeurbanne, France., Matera EL; Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université de Lyon, 69008 Lyon, France., Joseph B; Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, UMR CNRS 5246, Université de Lyon, 69100 Villeurbanne, France., Dumontet C; Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université de Lyon, 69008 Lyon, France.; Hospices Civils de Lyon, 69000 Lyon, France., Viricel W; Mablink Bioscience, 69 rue de la république, 69002 Lyon, France.

المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2021 Mar 09; Vol. 14 (3). Date of Electronic Publication: 2021 Mar 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Spasevska I; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Matera EL; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Chettab K; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Ville J; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Potier-Cartereau M; Inserm/University of Tours U1069, Nutrition-Croissance et Cancer (N2C), Tours, France., Jordheim LP; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Thieblemont C; Hemato-Oncology, Hospital Saint-Louis, APHP, Paris, France., Sahin D; Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland., Klein C; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland., Dumontet C; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France. charles.dumontet@chu-lyon.fr.; Hospices Civils de Lyon, Lyon, France.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Nov; Vol. 19 (11), pp. 2371-2381. Date of Electronic Publication: 2020 Aug 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Drug Antagonism*, Antineoplastic Agents, Immunological/*pharmacology , Calcium Channel Blockers/*pharmacology , Early Growth Response Protein 1/*antagonists & inhibitors , Rituximab/*pharmacology, Animals ; Antigens, CD20 ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; Disease Models, Animal ; Early Growth Response Protein 1/metabolism ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/mortality ; Mice ; NIH 3T3 Cells ; Prognosis ; Signal Transduction ; Treatment Outcome ; Xenograft Model Antitumor Assays

المؤلفون: Geneste A; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Duong MN; Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Epalinges, Switzerland., Molina L; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Conilh L; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France. conilh.louise@gmail.com., Beaumel S; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Cleret A; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Chettab K; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Lachat M; Hospices Civils de Lyon, Banque de tissus et cellules, 5 place d'Arsonval, 69003, Lyon, France., Jordheim LP; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Matera EL; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France., Dumontet C; Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052, CNRS 5286, 8 Avenue Rockefeller, 69008, Lyon, France.; Hospices Civils de Lyon, Services d'Hématologie, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.

المصدر: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2020 Aug 14; Vol. 21 (1), pp. 61. Date of Electronic Publication: 2020 Aug 14.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol Subsets: MEDLINE

مواضيع طبية MeSH: Adipocytes* , Culture Media, Conditioned* , Drug Resistance, Neoplasm*, Antineoplastic Agents/*pharmacology , Breast Neoplasms/*drug therapy , Lapatinib/*pharmacology , Protein Kinase Inhibitors/*pharmacology, Animals ; Cell Cycle/drug effects ; Cell Line ; Female ; Humans ; Mice, SCID

المؤلفون: Sauveur J; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Conilh L; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Beaumel S; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Chettab K; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Jordheim LP; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Matera EL; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France., Dumontet C; Cancer Research Center of Lyon, INSERM 1052/CNRS 5286/University of Lyon, Lyon, France.

المصدر: Pharmacology research & perspectives [Pharmacol Res Perspect] 2020 Aug; Vol. 8 (4), pp. e00617.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE

مواضيع طبية MeSH: Ado-Trastuzumab Emtansine/*pharmacology , Antineoplastic Agents, Immunological/*pharmacology , Breast Neoplasms/*drug therapy, Aneuploidy ; Antineoplastic Agents/pharmacology ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Female ; Humans ; Molecular Targeted Therapy ; Receptor, ErbB-2/metabolism ; Solute Carrier Proteins/genetics ; Tubulin/genetics